Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | PPARA | Q07869 | 9/20 | 0.53 |
| ▸ | PPARG | P37231 | 9/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | RXRA | P19793 | 1/20 | 0.43 |
| ▸ | RXRB | P28702 | 1/20 | 0.43 |
| ▸ | RXRG | P48443 | 1/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8935641 | 1.00 | SMN1; SMN2 (0.57) | SMN1; SMN2PPARAPPARGTDP1HTT | |
| SCHEMBL8935703 | 0.87 | SMN1; SMN2 (0.54) | SMN1; SMN2PPARAPPARGTDP1 | |
| SCHEMBL8935705 | 0.87 | SMN1; SMN2 (0.54) | SMN1; SMN2PPARAPPARGTDP1 | |
| SCHEMBL29213724 | 0.85 | TDP1 (0.54) | SMN1; SMN2PPARATDP1HTTKDM4E | |
| SCHEMBL4650644 | 0.83 | KMT2A (0.62) | SMN1; SMN2PPARAPPARGHTTALDH1A1 | |
| SCHEMBL8935639 | 0.83 | KMT2A (0.62) | SMN1; SMN2PPARAPPARGHTTALDH1A1 | |
| SCHEMBL6664136 | 0.83 | SMN1; SMN2 (0.49) | SMN1; SMN2PPARAPPARGTSHR | |
| SCHEMBL17633012 | 0.83 | SMN1; SMN2 (0.49) | SMN1; SMN2PPARAPPARGTSHR | |
| SCHEMBL8935961 | 0.83 | SMN1; SMN2 (0.49) | SMN1; SMN2PPARAPPARGTSHR | |
| SCHEMBL5861928 | 0.83 | SMN1; SMN2 (0.49) | SMN1; SMN2PPARAPPARGTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10662180-B2 | Proteasome chymotrypsin-like inhibition using PI-1833 analogs | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2020-05-26 | — | — | US | disclosed |
| US-20180215742-A1 | PROTEASOME CHYMOTRYPSIN-LIKE INHIBITION USING PI-1833 ANALOGS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2018-08-02 | — | — | US | disclosed |
| US-9878999-B2 | Proteasome chymotrypsin-like inhibition using PI-1833 analogs | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-20140073650-A1 | PROTEASOME CHYMOTRYPSIN-LIKE INHIBITION USING PI-1833 ANALOGS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2014-03-13 | — | — | US | disclosed |
| WO-2012129564-A2 | PROTEASOME CHYMOTRYPSIN-LIKE INHIBITION USING PI-1833 ANALOGS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2012-09-27 | — | — | WO | disclosed |
| US-20090069355-A1 | Bicyclic pyrazolone cytokine inhibitors | CLARK MICHAEL PHILIP | 2009-03-12 | — | — | US | disclosed |
| US-7482356-B2 | Bicyclic pyrazolone cytokine inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2009-01-27 | — | — | US | disclosed |
| US-7396850-B2 | Pyrazole derivative as PPAR modulator | ELI LILLY AND COMPANY (US) | 2008-07-08 | — | — | US | disclosed |
| US-20070203155-A1 | Compounds And Compositions As Ppar Modulators | IRM LLC (BM) | 2007-08-30 | — | — | US | disclosed |
| US-20070043220-A1 | Pyrazole derivative as ppar modulator | ELI LILLY AND COMPANY | 2007-02-22 | — | — | US | disclosed |
| US-7091237-B2 | Furan and thiophene derivatives that activate human peroxisome proliferator activated receptors | SMITHKLINE BEECHAM CORPORATION (US) | 2006-08-15 | — | — | US | disclosed |
| EP-1682551-A2 | BICYCLIC PYRAZOLONE CYTOKINE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2006-07-26 | — | — | EP | disclosed |
| EP-1583746-A1 | A PYRAZOLE DERIVATIVE AS PPAR MODULATOR | ELI LILLY AND COMPANY (US) | 2005-10-12 | — | — | EP | disclosed |
| WO-2005047287-A2 | BICYCLIC PYRAZOLONE CYTOKINE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2005-05-26 | — | — | WO | disclosed |
| US-20050113392-A1 | Bicyclic pyrazolone cytokine inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2005-05-26 | — | — | US | disclosed |
| US-20040157890-A1 | Furan and thiophene derivatives that activate human peroxisome profilerator activated receptors | GLAXO GROUP LIMITED (GB) | 2004-08-12 | — | — | US | disclosed |
| WO-2004063165-A1 | A PYRAZOLE DERIVATIVE AS PPAR MODULATOR | ELI LILLY AND COMPANY (US) | 2004-07-29 | — | — | WO | disclosed |
| US-5491167-A | INHIBITORS OF CHOLESTEROL BIOSYNTHESIS | SANKYO COMPANY, LIMITED (JP) | 1996-02-13 | — | — | US | disclosed |
| CN-1098099-A | The hexahydro naphthalene ester derivative, their preparation and their treatment are used | SANKYO CO (JP) | 1995-02-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157890-A1 | Furan and thiophene derivatives that activate human peroxisome profilerator activated receptors | PPARG, PPARD, PPARA | SMN1; SMN2 3688/4885PPARA 3/4885PPARG 1/4885 |
| US-10662180-B2 | Proteasome chymotrypsin-like inhibition using PI-1833 analogs | PSMB3, PSME3, PSMD3 | SMN1; SMN2 3198/4885PPARA 1881/4885PPARG 2888/4885 |
| US-20070203155-A1 | Compounds And Compositions As Ppar Modulators | PPARG, PPARA, PPARD | SMN1; SMN2 4476/4885PPARA 2/4885PPARG 1/4885 |
| US-20140073650-A1 | PROTEASOME CHYMOTRYPSIN-LIKE INHIBITION USING PI-1833 ANALOGS | PSMB3, PSME3, PSMD3 | SMN1; SMN2 3198/4885PPARA 1881/4885PPARG 2888/4885 |
| US-20180215742-A1 | PROTEASOME CHYMOTRYPSIN-LIKE INHIBITION USING PI-1833 ANALOGS | PSMB3, PSME3, PSMD3 | SMN1; SMN2 3198/4885PPARA 1881/4885PPARG 2888/4885 |
| US-20050113392-A1 | Bicyclic pyrazolone cytokine inhibitors | IL1B, IL1A, IL1RN | SMN1; SMN2 4630/4885PPARA 2729/4885PPARG 2922/4885 |
| US-20090069355-A1 | Bicyclic pyrazolone cytokine inhibitors | IL1B, IL1A, IL1RN | SMN1; SMN2 4630/4885PPARA 2729/4885PPARG 2922/4885 |
| US-20070043220-A1 | Pyrazole derivative as ppar modulator | PPARD, PPARG, PPARA | SMN1; SMN2 4737/4885PPARA 3/4885PPARG 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.